Co-Diagnostics, Inc. (NASDAQ:CODX) Short Interest Update – MarketBeat

This post was originally published on this site

Co-Diagnostics, Inc. (NASDAQ:CODXGet Rating) was the target of a large growth in short interest in October. As of October 31st, there was short interest totalling 2,350,000 shares, a growth of 15.8% from the October 15th total of 2,030,000 shares. Based on an average daily trading volume, of 430,000 shares, the days-to-cover ratio is presently 5.5 days.

Co-Diagnostics Stock Performance

CODX stock traded up $0.02 during trading on Monday, reaching $3.67. 108,954 shares of the company traded hands, compared to its average volume of 460,578. Co-Diagnostics has a 12 month low of $2.76 and a 12 month high of $10.90. The business has a 50 day simple moving average of $3.26 and a 200 day simple moving average of $4.47. The company has a market capitalization of $123.98 million, a price-to-earnings ratio of 7.79 and a beta of -1.04.

Co-Diagnostics (NASDAQ:CODXGet Rating) last issued its quarterly earnings data on Thursday, August 11th. The company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.25). Co-Diagnostics had a net margin of 28.50% and a return on equity of 8.21%. The company had revenue of $5.02 million for the quarter, compared to the consensus estimate of $20.50 million. As a group, research analysts forecast that Co-Diagnostics will post 0.09 EPS for the current year.

Institutional Investors Weigh In On Co-Diagnostics

Institutional investors have recently added to or reduced their stakes in the stock. Qube Research & Technologies Ltd bought a new stake in Co-Diagnostics during the first quarter valued at about $158,000. State of Tennessee Treasury Department boosted its holdings in Co-Diagnostics by 82.6% in the first quarter. State of Tennessee Treasury Department now owns 73,043 shares of the company’s stock worth $451,000 after acquiring an additional 33,043 shares in the last quarter. Kestra Advisory Services LLC acquired a new stake in Co-Diagnostics in the first quarter worth about $62,000. UMA Financial Services Inc. boosted its holdings in Co-Diagnostics by 17.5% in the first quarter. UMA Financial Services Inc. now owns 40,375 shares of the company’s stock worth $188,000 after acquiring an additional 6,000 shares in the last quarter. Finally, Tower Research Capital LLC TRC acquired a new stake in Co-Diagnostics in the third quarter worth about $93,000. Institutional investors own 22.56% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on CODX shares. HC Wainwright dropped their price target on Co-Diagnostics from $9.00 to $6.00 and set a “buy” rating on the stock in a research report on Monday. Sidoti downgraded Co-Diagnostics from a “buy” rating to a “neutral” rating and set a $5.00 price target on the stock. in a research report on Friday, August 12th.

Co-Diagnostics Company Profile

(Get Rating)

Co-Diagnostics, Inc, a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications.

Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Before you consider Co-Diagnostics, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Co-Diagnostics wasn’t on the list.

While Co-Diagnostics currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

This post was originally published on *this site*